FDA Approval of Tec-Dara: A Dramatic Leap Forward For Patients With Relapsed Multiple Myeloma

“About 83% of patients were still in remission at three years compared to only 20 to 30% with standard treatment. That’s probably one of the longest progression-free survivals we’ve ever seen in a relapsed myeloma patient population,” Dr. Lonial says. “…this is as close to a home run as you get.”

A New Option When Myeloma Returns

For many people living with multiple myeloma, the disease eventually returns after initial treatment, and doctors are tasked with finding new ways to keep the cancer under control.

The newly approved teclistamab-daratumumab combination — sometimes called Tec-Dara — offers a powerful new option. Teclistamab belongs to a newer class of treatments known as bispecific antibodies, which help the immune system recognize and attack myeloma cells.

By directing immune cells toward the cancer, therapies like these can reduce the amount of disease in the body and keep it under control longer — helping patients stay well and delay the need for another treatment.

“It’s thought that the combination of teclistamab and daratumumab has synergy. Daratumumab eliminates some of the cells that may limit the activity of the bispecific antibody, releasing more effective T-cell activity,” Dr. Lonial explains. “It’s immune therapy on steroids, if you will.”

For patients, that could mean:

• Longer periods where the disease is controlled
• Deeper responses to treatment
• Another option if the cancer returns after earlier therapy

The FDA approved the treatment through its National Priority Voucher program, an initiative designed to speed the review of promising therapies for serious diseases so patients can access them sooner.

What About Side Effects?

Like other immune-based treatments, bispecific antibodies can cause side effects. The most common early reaction is cytokine release syndrome (CRS), an immune response that can cause symptoms such as fever or low blood pressure.

Doctors say the severity of CRS with bispecific therapies like teclistamab is generally milder than what is often seen with CAR-T cell therapy, and physicians have developed strategies to manage it.

After the first few doses, many of the early immune-related side effects tend to resolve. Doctors then focus primarily on monitoring infections and supporting the immune system, which is common for patients receiving many myeloma treatments.

Signs of CRS might include:

• Fever
• Hypoxia (low oxygen levels in body’s tissues)
• Chills
• Hypotension (low blood pressure)
• Sinus tachycardia (increased heart rate)
• Headache
• Elevated liver enzymes

What Patients Should Know

This approval does not mean the treatment is right for everyone, but it adds an important new option for patients whose multiple myeloma returns after earlier therapy.

Patients should talk with their doctor about:

• Whether this treatment may be appropriate for them
• Where it fits among other available therapies

For many people living with multiple myeloma, the approval reflects how quickly treatment options are expanding — and how immune-based therapies are continuing to improve outcomes.

Questions To Ask Your Doctor

• Is Tec-Dara an option I should consider?
• What are the potential risks with this treatment?
• How will I be monitored during treatment?
• What side effects should I be aware of/monitor for?

Learn more about SurvivorNet's rigorous medical review process.

---